US Patent No: 7,556,963
Number of patents in Portfolio can not be more than 2000
Feline IL-18 nucleic acid molecules
Stats
-
Jul 7, 2009
Issued date -
Sep 1, 2006
filing date -
11/514,728
serial no -
In Force
status
Importance
Loading Importance Indicators...
Abstract
The present invention relates to canine and feline proteins. In particular, the present invention discloses feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain proteins. The present invention also includes feline interleukin-18, feline caspase-1, feline interleukin-12 single chain and canine interleukin-12 single chain nucleic acid molecules encoding such proteins, antibodies raised against such proteins and/or inhibitors of such proteins or nucleic acid molecules. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and/or inhibitors, as well as their use to evaluate and regulate an immune response in an animal.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art
| Patent Info | (Count) | # Cites | Year |
|---|---|---|---|
|
|
|||
| 5,912,324 Interferon-gamma (IFN-.gamma.) inducing factor (IGIF, IL-18) purified from murine liver | 18 | 1995 | |
| 5,942,224 Therapeutic agent for cat respiratory diseases and method of treatment using the same | 4 | 1995 | |
| 5,914,253 Recombinant production of murine interferon--.gamma. (IFN-.gamma.) inducing factor (IGIF, IL-18) | 11 | 1997 | |
|
|
|||
| 6,013,268 Methods for enhancement of protective immune responses | 19 | 1997 | |
|
|
|||
| 5,945,310 DNA encoding members of the IL-1 family, IL-1 delta | 12 | 1997 | |
|
|
|||
| 5,858,778 SF caspase-1 and compositions for making and methods of using the same | 7 | 1996 | |
|
|
|||
| 6,600,020 Canine interleukin 18 polypeptide | 1 | 1999 | |
|
|
|||
| 5,882,894 Nucleic acids encoding CR8 polypeptides, vector and transformed cell thereof, and expression thereof | 2 | 1995 | |
|
|
|||
| 5,985,863 Compositions and methods for decreasing IGIF and IFN-.gamma. production by administering an ICE inhibitor | 13 | 1996 | |
|
|
|||
| 5,919,790 Hydroxamate inhibitors of interleukin-1.beta. converting enzyme | 23 | 1997 | |
Patent Citation Ranking
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Jan 7, 2013 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jan 7, 2017 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jan 7, 2021 |
| Fee | Large entity fee | small entity fee | micro entity fee |
|---|---|---|---|
| Surcharge - 3.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
| Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
| Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |